Beijing Double-crane Pharmaceutical Co.,ltd.
| About us | DCPC has developed into a large modernized pharmaceutical group, which has established and expanded its operations in both domestic and world markets, with main business scope covering areas of new drug research, manufacturing, medicine operating and manufacturing drug-making equipment throughout all sections of drug research, production and circulation. As a firstly approved GMP enterprise. DCPC has already been advocating the idea-To vitalize our national medicine industry through high-tech and high quality, since it was listed in the stock exchange. DCPC has defined its three product series of Antibiotics, Infusion Fluid and Natural Drugs for future development. DCPC has a well-thought-out plan for future. So it defines the next three-year aim of development: Devoting major efforts to developing synthetic antibiotics series such as Quinolones and Sulfonamides, where DCPC will play a leading role in China; Devoting major efforts to developing infusion fluid series, where DCPC will build itself as a specialized, large-scale infusion fluid group in China; Trying its best to develop natural drug, where DCPC will accomplish the modernization of natural drugs with modern medicinal technique. Beijing Double-Crane Modern Medicinal Technology Limited Liability Company, which is the R & D center of DCPC, was reformed from Beijing Institute of Pharmaceutical Industry and Pharmaceutical Institute of DCPC through reorganization of assets. There are more than 80 achievements of science and research including 4 of state level, more than 20 ministry level, and over 60 has been applied to production or technology transfer. All of them created significant social effect and economic benefit. We are sure that you should be satisfied with our products and service. |
|---|---|
| Industry Focus | Drugs & Medications, Pharmaceutical Chemicals |
| Business Type | Manufacturer |
| Products/Services | Ofloxacin;Atropin sulphate;Clotrimazole;Metformin hcl;Metoclopramide hcl;Metronidazole;Paracetamol;Puerarin;Sulfamethoxazole;Sodium para-amino salicylate;Vitamin c; |
| Our Markets | Eastern Asia |
| No. of Employees | Above 1000 People |
| Annual Sales Range(USD) | Above US$100 Million |
